Salvianolic acid B
Salvianolic acid B (Sal B) is a water-soluble, polyphenolic bioactive compound derived from Salvia miltiorrhiza (Danshen), a widely used medicinal herb in traditional Chinese medicine.
Salvianolic acid B (Sal B) is a water-soluble, polyphenolic bioactive compound derived from Salvia miltiorrhiza (Danshen), a widely used medicinal herb in traditional Chinese medicine. As a major constituent of Danshen extracts, salvianolic acid B has emerged as a subject of significant scientific interest in recent years due to its multi-targeted pharmacological properties. The compound exhibits potent antioxidant, anti-inflammatory, and neuroprotective effects, operating through modulation of multiple intracellular Signaling pathways including the NF-κB axis, ferroptosis regulation, and various growth factor Signaling cascades. Its therapeutic potential spans a diverse range of acute and chronic diseases—from cerebrovascular and cardiovascular conditions to inflammatory disorders—though clinical translation has been limited by challenges including poor penetration across the blood–brain barrier and suboptimal bioavailability, which have prompted recent advances in nanoparticle-based delivery strategies.
Where the papers sit
9 papers from the last 6 months study Salvianolic acid B directly · updated from PubMed 1 Nov 2026
Study type 0 clinical trials · 8 preclinical · 1 unclassified
Themes one subject
Those 9 are all about one subject.
-
Preclinical Therapeutic Applications
Neurovascular, inflammatory, pulmonary and epithelial injuries are the main settings for salvianolic acid B research. Reported mechanisms include CPT1/HIF-1α, Nrf2-dependent ferroptosis suppression, TNFR1, NF-κB and TGF-β1/Smad3 signaling. Intranasal and liposomal formulations are being explored to improve delivery and enhance treatment effects. Analytical separation work sits alongside these therapeutic studies, leaving no single dominant disease direction.
Papers
The 9 papers from the last 6 months that study Salvianolic acid B directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Preclinical Therapeutic Applications (9)
- Simultaneous separation of two indicator constituents in Salvia miltiorrhiza Bge. from compound Chinese medicine using ionic Liquid@Covalent organic framework (IL@COF) discs. Journal of chromatography. A · 28 Jul 2026 PMID 42520452
- A Study on the Effects of Intranasally Administered Liquid Crystalline Nanoparticles Loaded with Salvianolic Acid B in Vascular Dementia. Molecular neurobiology · 21 Jul 2026 PMID 42481908
- Danshen-Chuanxiong alleviates cerebral ischemia by regulating carnitine metabolism and angiogenesis via activating CPT1/HIF-1α signaling axis. Journal of ethnopharmacology · 10 Jul 2026 PMID 42431282
- Salvianolic Acid B Attenuates Excitotoxic Neuronal Injury After Transient Cerebral Ischemia. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379790
- Liposomal Salvianolic Acid B Enhances ALA-PDT in Oral Leucoplakia via ROS and AKT/mTOR Signalling. International dental journal · 3 Jun 2026 PMID 42235408
- Nuclear Factor Erythroid 2-Related Factor 2-Dependent Ferroptosis Suppression by Salvianolic Acid B Preserves Microvascular Integrity and Reduces Risk Factors for Hemorrhagic Transformation After Cerebral Infarction. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 26 May 2026 PMID 42186809
- Targeting TNFR1 by salvianolic acid B alleviates sepsis-induced acute lung injury and pulmonary-intestinal epithelial barrier damage. Phytomedicine : international journal of phytotherapy and phytopharmacology · 23 May 2026 PMID 42176509
- Targeting 5-methylcytosine RNA methylation-mediated CX26/IκBα/NF-κB signaling by salvianolic acid B attenuates rheumatoid arthritis progression. Phytomedicine : international journal of phytotherapy and phytopharmacology · 20 May 2026 PMID 42160901
- Tanshinone IIA, salvianic acid A, salvianolic acid B, and hydroxysafflor yellow A reduce cerebral injury via TGF-β1/Smad3 pathway. Neuroscience letters · 8 May 2026 PMID 42102961
By study type
Preclinical: animal, cell and lab studies (8)
- Simultaneous separation of two indicator constituents in Salvia miltiorrhiza Bge. from compound Chinese medicine using ionic Liquid@Covalent organic framework (IL@COF) discs. Journal of chromatography. A · 28 Jul 2026 PMID 42520452
- A Study on the Effects of Intranasally Administered Liquid Crystalline Nanoparticles Loaded with Salvianolic Acid B in Vascular Dementia. Molecular neurobiology · 21 Jul 2026 PMID 42481908
- Salvianolic Acid B Attenuates Excitotoxic Neuronal Injury After Transient Cerebral Ischemia. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379790
- Liposomal Salvianolic Acid B Enhances ALA-PDT in Oral Leucoplakia via ROS and AKT/mTOR Signalling. International dental journal · 3 Jun 2026 PMID 42235408
- Nuclear Factor Erythroid 2-Related Factor 2-Dependent Ferroptosis Suppression by Salvianolic Acid B Preserves Microvascular Integrity and Reduces Risk Factors for Hemorrhagic Transformation After Cerebral Infarction. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 26 May 2026 PMID 42186809
- Targeting TNFR1 by salvianolic acid B alleviates sepsis-induced acute lung injury and pulmonary-intestinal epithelial barrier damage. Phytomedicine : international journal of phytotherapy and phytopharmacology · 23 May 2026 PMID 42176509
- Targeting 5-methylcytosine RNA methylation-mediated CX26/IκBα/NF-κB signaling by salvianolic acid B attenuates rheumatoid arthritis progression. Phytomedicine : international journal of phytotherapy and phytopharmacology · 20 May 2026 PMID 42160901
- Tanshinone IIA, salvianic acid A, salvianolic acid B, and hydroxysafflor yellow A reduce cerebral injury via TGF-β1/Smad3 pathway. Neuroscience letters · 8 May 2026 PMID 42102961
Unclassified: not yet indexed with MeSH (1)
- Danshen-Chuanxiong alleviates cerebral ischemia by regulating carnitine metabolism and angiogenesis via activating CPT1/HIF-1α signaling axis. Journal of ethnopharmacology · 10 Jul 2026 PMID 42431282
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-07-26. Last written: 2026-08-27 by GPT. Drafted by language models from published abstracts; not medical advice.